Background Graft-versus-host disease (GVHD) is the major cause of non-relapse mortality after allogeneic haemopoietic stem-cell transplantation (SCT). The severity of symptoms at the onset of GVHD does not accurately define risk, and thus most patients are treated alike with high dose systemic corticosteroids. We aimed to define clinically meaningful risk strata for patients with newly diagnosed acute GVHD using plasma biomarkers.
Introduction
The ability of allogeneic haemopoietic stem cell transplantation (SCT) to cure haematological malig nancies is due, in part, to the graftversusleukaemia (GVL) effect mediated by alloreactive T cells in the donor graft. But GVL effects remain closely associated with graftversushost disease (GVHD), which is mediated by those same T cells and natural killer cells. 1 GVHD, which occurs in both acute and chronic forms, remains the major cause of death without relapse of primary disease or nonrelapse mortality. [2] [3] [4] The primary treatment of acute GVHD, high dose systemic gluco corticoids, has not changed in 40 years. 5 Only a third of patients achieve durable responses to initial cortico steroid therapy and survival among the remaining patients is poor. 6 An important obstacle to the development of new therapies of acute GVHD is the inability to determine risk for an individual patient at the onset of symptoms. Risk of mortality correlates with maximum clinical severity in current grading systems, which can only be assigned retrospectively after the response to treatment is known. [7] [8] [9] Thus, at disease onset, most patients are treated alike with high dose corticosteroids resulting in substantial numbers of patients who are both under treated and overtreated. Overtreated patients who are likely to respond to low doses of glucocorticoids have additional infectious risks associated with profound immunosuppression and morbidities such as avascular necrosis of bone and diabetes mellitus. [10] [11] [12] [13] An excess of 70-90% of undertreated patients who develop steroid resistant acute GVHD die. [14] [15] [16] We aimed to define clinically meaningful risk strata for patients with newly diagnosed acute GVHD using plasma biomarkers.
Methods

Clinical specimens and study design
The study population for the training and test sets consisted of patients with new onset acute GVHD grade I-IV from the University of Michigan, Ann Arbor, MI, USA (n=360) and the University of Regensburg, Germany (n=132), who provided blood samples at the onset of acute GVHD on institutional review boardapproved protocols at e22
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See Online for appendix each centre. Both centres used standardised guidance that was developed through a longstanding collaboration to minimise variability in the diagnosis and estimation of the severity of acute GVHD. 17 Patients were randomly assigned (2:1) to the training or test set using a random number generator, conditional on the final two datasets having the same median day of onset. The initial dose of systemic corticosteroid therapy for GVHD treatment was between 1-2 mg/kg per day of methylprednisolone, as determined by the treating physician who used best medical judgment that considered a range of factors, including but not limited to, severity and timing of GVHD, donor source, infectious history, and relapse risk. 300 patients from multiple centres who provided blood samples at the time of enrolment on Blood and Marrow Transplant Clinical Trial Network (BMT CTN) clinical trials of primary therapy for GVHD (appendix p 2) formed an independent multicentre validation set. Patients from the University of Michigan who participated in BMT CTN clinical trials were included only in the training and test set.
Between April 13, 2000, and May 7, 2013, plasma samples were collected prospectively within 48 h before or after the initiation of glucocorticoid therapy from patients who developed GVHD symptoms after SCT. Clinical grading of GVHD was done according to modified Glucksberg criteria 9 (appendix p 3). The overall clinical grade (I-IV) combines the stages of three individual target organs (skin, liver, and gastrointestinal tract. ELISAs were done as previously described.
18-21
Procedures
The primary endpoint, nonrelapse mortality at 6 months from GVHD onset, was defined as any death without preceding relapse. Treatment response was a secondary endpoint that required improvement in overall clinical (modified Glucksberg) GVHD grade on day 28 after onset without additional systemic immunosuppressants. Complete response was defined as resolution of all target organ symptoms. Partial response was defined as an improvement of any organ stage by at least one stage without increase in any other target organ stage. All other treatment outcomes were classified as non response. We categorised GVHD responses as durable if patients achieved complete response by day 28 and remained in complete response at 6 months postonset. Patients who died before response assessments were considered nonresponders. Data for 6 month GVHD staging were available only for patients in the training and test sets from the University of Michigan and the University of Regensburg (n=492).
Statistical analysis
We used a competing risks regression model according to the methods of Fine and Gray 22 using logtransformed biomarker concentrations at the onset of GVHD from the training set alone to predict 6 month nonrelapse mortality in the training set. In the resulting algorithm, every biomarker was assigned a weight computed by the model that best fit the data of the training set alone. The sum of these weighted concentrations led to a predicted probability for each individual patient. Models with different numbers of biomarkers (from one to five) were fit to the training set alone. For a model to warrant examination, each weighted biomarker needed to be statistically significant and the model needed to be statistically superior (by the likelihood ratio test) to a model where all weights were zero. We then compared the remaining models to each other using likelihood ratio tests and Akaike's Information Criterion (AIC) to determine which models were most parsimonious. 23 We then rank ordered the probability of nonrelapse mortality, p, in the training set and identified thresholds of p to define three scores such that 1 represented an excellent outcome (nonrelapse mortality ≤10%) and 3 a poor outcome (nonrelapse mortality >40%), and thus nonrelapse mortality would increase by 15% on average with each increasing score. Multiple thresholds that met these criteria were evaluated in the test set; representative threshold pairs and their corresponding nonrelapse mortalities are shown in appendix p 7. Of note, we did not compare organ specific biomarkers to the algorithm in patients with single organ disease because of the relative paucity of such patients.
Overall differences in patient characteristics between the training, test, and multicentre validation set were assessed with χ² test of association for categorical values and a Wilcoxon rank sum test for continuous values. Estimation and inference for nonrelapse mortality and relapse rates were based on the methods of Gray 24 and Fine and Gray, respectively. 22 Estimation and inference for overall survival were based on Cox regression, and estimation and inference for day 28 complete response and complete or partial response rates were based on logistic regression. Empirical area under the receiver operating characteristic curves for nonrelapse mortality by 6 months was computed nonparametrically. All analyses were done with R statistical package version 3.0.1 (R Development Core Team, Vienna, Austria).
Role of the funding source
The sponsors of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. JEL and JLMF had full access to all data in the study and held joint final responsibility for the decision to submit for publication.
Results
The clinical characteristics of the twocentre training and test sets and the multicentre BMT CTN validation set are shown in appendix p 8. The multicentre validation set differed significantly from the test and training sets in their overall distributions of age, stemcell source, indication for SCT, day of onset and severity of GVHD, and GVHD prophylaxis (appendix p 8). Patients in the multicentre validation set were older than those in the other sets (median age 52 years [IQR 41-60] vs 48 years , more likely to receive marrow as a stem cell source (21% vs 11%), and they developed GVHD later after SCT (median 34 days vs 27 days). They were also less likely to have highrisk disease (20% vs 43%), to have grade I GVHD at onset (17% vs 37%), or to receive a calcineurin inhibitorcontaining GVHD prophylaxis (79% vs 96%).
To develop an algorithm that would be reliable in a multicentre setting, we collected blood samples from 492 SCT patients at two centres (the University of Michigan and the University of Regensburg) with similar diagnostic and therapeutic approaches to acute GVHD and randomly divided them into a training set (n=328) and a test set (n=164). For all 492 patients, we retrospectively analysed plasma samples for con cen trations of five biomarkers previously shown to have prognostic value (IL2Rα, TNFR1, REG3α, Elafin, and ST2). [18] [19] [20] [21] 25 The two previously reported biomarkers with the weakest prognostic value (hepatocyte growth factor and interleukin 8) were not included. 18 We used competing risks regression to develop an algorithm in the training set to compute a predicted probability (p) of nonrelapse mortality within 6 months of GVHD diagnosis. We then determined that an algorithm of the three biomarkers assigned the greatest weights (TFNR1, ST2, and REG3α) did as well as the fivebiomarker algorithm. The final algorithm was: log[log(1p)] = -9·169 + 0·598(log 2 TNFR1) -0·028 (log 2 REG3α) + 0·189 (log 2 ST2). Using the three biomarker algorithm, we determined the (p) for all patients in the training set, rank ordered them from lowest to highest, and identified thresholds that met predetermined desirable criteria for three GVHD scores (upper threshold for Ann Arbor 1, non relapse mortality ≤10%; and lower threshold for Ann Arbor 3 nonrelapse mortality ≥40%) so that nonrelapse mortality would increase 15% on average with each increasing score. A range of thresholds met these criteria, and we chose one near the median of each range to define the Ann Arbor scores.
This approach defined three distinct scores whose risk of nonrelapse mortality significantly increased with each increasing grade at both 6 months and 12 months after the onset of GVHD in the training set ( figure 1A ). We applied the algorithm to the test set (n=164) and noted very similar risks of nonrelapse mortality (figure 1B). We next applied the biomarker algorithm to an independent validation set of SCT patients enrolled on BMT CTN trials for primary GVHD therapy (n=300) and noted similarly significant differences in non relapse mortality (figure 1C). Relapse, which was treated as a competing risk for nonrelapse mortality, did not differ significantly between the three Ann Arbor GVHD scores in any of the datasets (figure 1D-F). The differences in nonrelapse mortality thus resulted in significant differences in overall survival at 1 year among these three scores after the onset of GVHD ( figure 1G-I) .
In all three datasets (training, test and validation), the cumulative incidence of nonrelapse mortality significantly increased as the Ann Arbor score increased (p<0·0001; NRM=non-relapse mortality. The response of GVHD to treatment 28 days later serves as a surrogate endpoint for longterm survival. 15, 26 The proportion of all 792 patients who responded to therapy (generally systemic corticosteroids; appendix p 9) was significantly different for each of the Ann Arbor scores into which our algorithm catergorised patients (81% for score 1; 68% for score 2; 46% for score 3; p<0·0001 for all comparisons). We noted near similar proportions in each dataset for complete response and partial response (figure 2A-C) and for complete response alone ( figure 2D-F) .
A standard initial glucocorticoid dose for primary treatment of GVHD is 2 mg/kg per day of methyl prednisolone, 5 but clinicians might choose lower doses or, in the case of limited skin GVHD (<50% body surface area), delay systemic treatment to avoid toxicity. 27, 28 Intensity of initial steroid treatment of patients in the training and test sets (n=492) did not affect outcomes by Ann Arbor score (appendix p 16). The responses by Ann Arbor score for patients with limited skin GVHD (Glucksberg grade I) who were treated (n=96) or not treated (n=98) with systemic steroids at diagnosis were similar (p=0·54; appendix p 16). Likewise, the responses by Ann Arbor score for patients with Glucksberg grade II or greater treated with 2 mg/kg per day of corticosteroids (n=137) or less than 2 mg/kg per day (n=64) were also similar (p=0·74; appendix p 16). We assessed the durability of treatment response in all 492 patients from the Universities of Michigan and Regensburg. A durable response, defined as complete response for at least 6 months without a recurrence of GVHD symptoms, was significantly less likely in patients with Ann Arbor 3 GVHD than in patients with Ann Arbor 1 GVHD, regardless of organ involvement at GVHD onset (table 2) . Patients who presented with GVHD skin rash alone and were classified as Ann Arbor 1 were significantly more likely to achieve durable responses than those who were classified as Ann Arbor 3 (table 3) . Likewise, patients with lower gastrointestinal GVHD at onset were significantly more likely to achieve durable responses if their GVHD score was Ann Arbor 1 rather than was Ann Arbor 3. The organ specific Glucksberg grade also correlated with durable response in these patients (appendix p 15).
74 (26%) of 286 patients from the Universities of Michigan and Regensburg (training and test sets) who presented with skin GVHD only subsequently developed lower gastrointestinal GVHD; of this group, 14 (41%) of 34 presented with Glucksberg 1 and Ann Arbor 3 compared with 18 (23%) of 67 with Ann Arbor 2 and 17 (19%) of 89 with Ann Arbor 1 GVHD (p=0·042). Thus, the Ann Arbor score predicted the development of gastrointestinal GVHD, but the extent of skin rash did not (table 3) . Patients with Ann Arbor 3 GVHD were 1·78 times more likely to later develop involvement of the gastrointestinal tract (at a median of 12 days [IQR 4-34]) than patients with Ann Arbor 1 GVHD (p=0·025).
We did all subsequent analyses on the validation set because it represented a wide range of supportive care and GVHD prophylaxis practices at a large number of centres, and in all patients the GVHD was deemed significant enough to require treatment with systemic steroids and an experimental drug. As expected, the clinical grade of GVHD at onset did not always correlate with either response to treatment or with nonrelapse mortality (appendix p 5). Despite the small sample sizes available for this subset analysis, the same biomarker algorithm defined three distinct risk strata for non relapse mortality within each Glucksberg grade ( figure 3A-C) . Surprisingly, similar proportions of patients were assigned to each Ann Arbor score in each of the three Glucksberg grades. Patients with the higher Ann Arbor scores were also usually less likely to respond to treatment ( figure 3D-F) . We did not find strong evidence for an interaction between severity of symptoms and Ann Arbor score on nonrelapse mortality (p=0·11),
Sample size (n) Durable response, n (%) p value vs AA1
vs AA2 better visualise this difference in AIC, we determined the hazard ratios (HR) for nonrelapse mortality in univariate models for both staging systems using moderate GVHD (Ann Arbor 2 or Glucksberg II) as the reference group (appendix p 10). We then fit a multivariate model with simultaneous adjustment for both Ann Arbor score and Glucksberg grades. Patients with Ann Arbor score 3 had significantly higher risk for nonrelapse mortality than patients with Ann Arbor 2 (figure 4A, p=0·0048) and patients with Ann Arbor 1 have significantly less risk (p=0·0020) than patients with Ann Arbor 2. By contrast, the 95% CIs for the HRs of the Glucksberg grades encompass 1·0, showing an absence of statistical significance between the grades. The area under the receiver operating characteristic curve for Ann Arbor scores (0·71) was also higher than that for Glucksberg grading (0·57), although this difference was not statistically significant ( figure 4B ). Several clinical risk factors, such as donor type, age, conditioning regimen intensity, and HLAmatch, can predict for treatment response and survival in patients with GVHD. 15, [29] [30] [31] With Ann Arbor 2 as a reference, we noted that Ann Arbor 1 predicted a lower risk of non relapse mortality (range 0·16-0·32) and Ann Arbor 3 a higher risk of nonrelapse mortality (1·4-2·9), regardless of the presence of these clinical risk factors (appendix p 11). Indeed, patients with HLAmismatched donors were significantly more likely to have Ann Arbor 3 GVHD in all three datasets (appendix pp [12] [13] [14] . Regardless of the presence of these clinical risk factors, we noted that Ann Arbor 1 predicted a lower risk of non relapse mortality (range 0·16-0·32) and Ann Arbor 3 a higher risk of nonrelapse mortality (1·4-2·9), with Ann Arbor 2 as a reference.
All presentations (n=492)
Discussion
Maximum clinical severity of GVHD in symptombased grading systems correlates with survival, but these systems are not often able to guide treatment at symptom onset. As a result, clinicians do not intensify immuno suppressive treatment of GVHD until primary therapy has failed. In our study, we have developed and validated an algorithm using biomarkers that define three GVHD severity scores, each with a distinct risk of nonrelapse mortality. We observed that our Ann Arbor GVHD scores defined risk across the full range of clinical presentations.
A higher Ann Arbor score predicted the development of gastrointestinal GVHD in patients who presented without gastrointestinal symptoms, which clinical grading did not. Most deaths of patients with GVHD that are not caused by relapse of primary disease are due to poor response to treatment of GVHD in the gastro intestinal tract. It is therefore of great interest that the three biomarkers included in this algorithm (TNFR1, ST2, and REG3α) possess biological relevance to gastro intestinal GVHD. TNFR1, a surrogate for TNFα, is produced by T cells and monocytes and amplifies gastro intestinal injury. 32, 33 TNFα regulates ST2 that, together with its ligand interleukin 33 (a member of the interleukin 1 family), affects inflammatory bowel disease activity. 34 REG3α, which we previously validated as a gastrointestinal GVHD specific biomarker, 20 is produced primarily by Paneth cells and protects the gastrointestinal epithelium from infectious damage. 35 The concentrations of these biomarkers at GVHD onset seem to reflect gastrointestinal tract disease activity that does not correlate with the severity of gastrointestinal symptoms at that time.
An important strength of our study is the biomarker algorithm's ability to define risk accurately despite differences in clinical severity at presentation and treatment intensity. In the dataset from the University of Michigan and University of Regensburg, about half of patients who presented with rashes of less than 50% body surface area (Glucksberg grade 1)-ie, 20% of all patients, never required treatment with systemic steroids. In the multicentre BMTCTN dataset, all patients received treatment with systemic glucocorticoids and an experimental drug, but the algorithm correctly identified patients at low risk of nonrelapse mortality.
Previous studies established correlations between either individual GVHD biomarkers or their com binations and clinical outcomes, but they were not consistent among different clinical centres (panel). [18] [19] [20] [21] 25 The biomarker algorithm developed in our study advances the previous work, but important limitations remain. First, although the algorithm predicts outcomes better than clinical symptoms, it still has fairly poor predictive power and is most useful for patients who score at either end. Second, the algorithm's ability to guide prospective therapy is yet to be shown. Nevertheless, the algorithm should prove useful in the design of clinical trials. For example, a low score might be used as an exclusion criterion for patients with severe clinical symptoms (eg, voluminous diarrhoea) from a trial of an investigational drug. Such patients who are likely to respond to standard therapy benefit by avoiding exposure to the risks of an experimental drug, and the trial also benefits by enrichment for patients who are less likely to respond to standard therapy. Conversely, a low score could be an inclusion criteria to restrict exposure to lengthy glucocorticoid regimens. A high score (about 23% of all GVHD) could be used as inclusion criterion for a trial of intensive primary therapy. This approach would be particularly beneficial for patients with mild symptoms but who are less likely to respond to standard therapy and who might otherwise need to wait until primary treatment has failed before the initiation of an experimental modality. If a clinical trial is unavailable, a high score could lend confidence to the diagnosis of GVHD when a biopsy is equivocal, and a low score in a patient with a limited rash might support the use of topical treatment or watchful waiting.
Studies are currently underway to improve the predictive value of the algorithm. An attractive feature of the statistical methods used here is its ability to incorporate additional risk factors as they become known. For example, although donor type is not currently incorporated into grading systems of GVHD, some studies show worse survival for patients with GVHD after an SCT from an unrelated volunteer donor. 15, 26 Patients with HLAmismatched donors were significantly more likely to have Ann Arbor 3 GVHD in all three datasets. Possibly, the incorporation of such a clinical characteristic, or even the nature of the GVHD symptoms at their onset, might improve the algorithm's predictive power, and in the training and test sets, organ specific Glucksberg grade was also correlated with durable response. The algorithm has also not yet been adequately assessed in patients who have both GVHD and other conditions, such as sinusoidal obstructive syndrome or bacterial sepsis, or who have uncommon GVHD presentations, such as isolated severe liver GVHD. The use of an algorithm at serial timepoints could prove useful, particularly in patients whose response to treatment is slow or partial. But much larger datasets will be required to test adequately such possibilities and combinations, probably on the order of several thousand patients. Yet we anticipate future versions of this algorithm will prove increasingly useful and accelerate the development of precision medicine for SCT patients.
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